Financials in USD. Standardized financial statements.
A compact view of how Alpine Immune Sciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $58.88M | $30.06M | $23.44M | $9.34M | $1.74M | $705,000 | $1.73M | $2.95M | $492,000 | $0 |
| Revenue Growth? | +95.8% | +28.2% | +151.1% | +436.5% | +146.8% | -59.3% | -41.3% | +499.6% | 0.0% | 0.0% |
| Cost of Revenue? | $80.90M | $597,000 | $620,000 | $27.18M | $35.85M | $28.97M | $10.63M | $143,000 | $66,000 | $0 |
| Gross Profit? | -$22.03M | $29.47M | $22.82M | -$17.85M | -$34.11M | -$28.27M | -$8.89M | $2.81M | $426,000 | $0 |
| Gross Margin? | -37.4% | +98.0% | +97.4% | -191.2% | -1960.2% | -4009.2% | -513.9% | +95.2% | +86.6% | 0.0% |
| Operating Expenses? | $103.13M | $88.21M | $73.30M | $38.08M | $45.31M | $37.33M | $16.70M | $31.90M | $22.90M | $14.49M |
| Operating Income? | -$44.25M | -$58.15M | -$49.86M | -$28.75M | -$43.57M | -$37.83M | -$14.97M | -$31.90M | -$22.90M | -$14.49M |
| EBITDA? | -$31.41M | -$51.77M | -$49.35M | -$25.59M | -$39.45M | -$35.33M | -$14.19M | -$31.90M | -$22.90M | -$14.10M |
| Income Before Tax | -$32.08M | -$55.43M | -$50.42M | -$27.95M | -$41.85M | -$36.85M | -$7.98M | -$31.46M | -$22.82M | -$15.04M |
| Income Tax Expense | $103,000 | $2.33M | -$87,000 | -$6,000 | $682,000 | -$366,000 | -$200,000 | -$143,000 | -$66,000 | $0 |
| Net Income? | -$32.18M | -$57.76M | -$50.33M | -$27.94M | -$42.53M | -$36.49M | -$7.78M | -$31.46M | -$22.82M | -$15.04M |
| EPS? | $-0.64 | $-1.73 | $-1.98 | $-1.34 | $-2.32 | $-2.63 | $-1.20 | $-8.12 | $-9.74 | $-6.59 |
| Diluted EPS? | $-0.64 | $-1.73 | $-1.98 | $-1.34 | $-2.32 | $-2.63 | $-1.20 | $-8.12 | $-9.74 | $-6.59 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality